-
Ionis Pharmaceuticals NASDAQ:IONS For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.
Location: 2855 Gazelle Ct, California, 92010-6670, US | Website: www.ionispharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
6.098B
Cash
2.086B
Avg Qtr Burn
-86.49M
Short % of Float
6.83%
Insider Ownership
0.84%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QALSODY™ (Tofersen) Details Amyotrophic lateral sclerosis | Approved Update | |
SPINRAZA Details Spinal muscular atrophy | Approved Quarterly sales | |
WAINUA™ Eplontersen (AKCEA-TTR-LRx) Details Transthyretin amyloidosis | Approved Quarterly sales | |
IONIS-APOCIII-LRx (Olezarsen) Details Familial chylomicronemia syndrome | PDUFA Approval decision | |
Donidalorsen (IONIS-PKK-LRx) Details Hereditary angioedema | NDA Submission | |
Eplontersen (AKCEA-TTR-LRx) Details Diabetic cardiomyopathy, Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy | Phase 3 Data readout | |
Ulefnersen (ION363 ) Details Amyotrophic lateral sclerosis | Phase 3 Data readout | |
Bepirovirsen (IONIS-HBVRx) Details Hepatitis B | Phase 3 Data readout | |
Zilganersen (ION373) Details Alexander Disease | Phase 3 Data readout | |
IONIS-APOCIII-LRx (Olezarsen) Details Severe hypertriglyceridemia | Phase 3 Data readout | |
Pelacarsen Details Heart disease, Cardiovascular disease | Phase 3 Data readout | |
ION582 Details Angelman Syndrome | Phase 3 Initiation | |
ION839 / AZD2693 Details Non-alcoholic steatohepatitis | Phase 2b Data readout | |
ION224 Details Non-alcoholic steatohepatitis | Phase 2b Update | |
IONIS-MAPTRx (BIIB080) Details Alzheimer's disease | Phase 2 Data readout | |
IONIS-FB-LRx Details IgA nephropathy | Phase 2 Update | |
Tominersen (IONIS-HTT Rx) Details Huntington's disease | Phase 2 Update | |
IONIS-AGT-LRx Details Heart failure, Pulmonary hypertension | Phase 2 Update | |
IONS356 (PLP1) Details Pelizaeus-Merzbacher disease | Phase 1/2 Data readout | |
IONIS-ENaC-2.5Rx (antisense medicine) Details Cystic fibrosis | Failed Discontinued | |
Fesomersen (IONIS-FXI-LRx) Details Hepatitis B | Failed Discontinued | |
IONIS-FB-LRx Details Geographic atrophy | Failed Discontinued | |
Cimdelirsen (IONIS-GHR-LRx) Details Acromegaly | Failed Discontinued |